Literature DB >> 6389104

Degradation of insulin-like growth factors I and II by a human insulin degrading enzyme.

R A Roth, M L Mesirow, K Yokono, S Baba.   

Abstract

A human insulin degrading enzyme purified from IM-9 lymphocytes was tested for its ability to degrade insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II). Degradation of these molecules was assessed by trichloroacetic acid precipitation, binding to specific receptors and chromatography on Sephadex G-50. All three techniques indicated that the enzyme readily degraded IGF-II and slightly degraded IGF-I. The IGF-II degrading activity chromatofocused with the insulin degrading activity and was absorbed by specific antibodies to the insulin degrading enzyme. These studies indicate, therefore, that a human insulin degrading enzyme can degrade IGF-II and, to a lesser extent, IGF-I.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389104     DOI: 10.3109/07435808409035411

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  12 in total

1.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Toxoplasma gondii toxolysin 4 is an extensively processed putative metalloproteinase secreted from micronemes.

Authors:  Julie Laliberté; Vern B Carruthers
Journal:  Mol Biochem Parasitol       Date:  2011-01-26       Impact factor: 1.759

Review 3.  Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.

Authors:  E Malito; R E Hulse; W-J Tang
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

Review 4.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

5.  Gene expression of the dibasic-pair cleaving enzyme NRD convertase (N-arginine dibasic convertase) is differentially regulated in the GH3 pituitary and Mat-Lu prostate cell lines.

Authors:  A G Winter; A R Pierotti
Journal:  Biochem J       Date:  2000-11-01       Impact factor: 3.857

6.  Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.

Authors:  Julie Charton; Marion Gauriot; Jane Totobenazara; Nathalie Hennuyer; Julie Dumont; Damien Bosc; Xavier Marechal; Jamal Elbakali; Adrien Herledan; Xiaoan Wen; Cyril Ronco; Helene Gras-Masse; Antoine Heninot; Virginie Pottiez; Valerie Landry; Bart Staels; Wenguang G Liang; Florence Leroux; Wei-Jen Tang; Benoit Deprez; Rebecca Deprez-Poulain
Journal:  Eur J Med Chem       Date:  2014-12-04       Impact factor: 6.514

7.  In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.

Authors:  Wei-Jie Zhang; Xiao Luo; Zhan-Yun Guo
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

8.  Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.

Authors:  Qing Guo; Marika Manolopoulou; Yao Bian; Alexander B Schilling; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2009-11-05       Impact factor: 5.469

9.  Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis.

Authors:  Julie Charton; Marion Gauriot; Qing Guo; Nathalie Hennuyer; Xavier Marechal; Julie Dumont; Malika Hamdane; Virginie Pottiez; Valerie Landry; Olivier Sperandio; Marion Flipo; Luc Buee; Bart Staels; Florence Leroux; Wei-Jen Tang; Benoit Deprez; Rebecca Deprez-Poulain
Journal:  Eur J Med Chem       Date:  2014-04-04       Impact factor: 6.514

10.  Cellular distribution of insulin-degrading enzyme gene expression. Comparison with insulin and insulin-like growth factor receptors.

Authors:  C A Bondy; J Zhou; E Chin; R R Reinhardt; L Ding; R A Roth
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.